TAURINE and HCC PATIENTS

Ain Shams University

Status: Completed

Conditions: Taurine in HCC

Treatments: Diagnostic Test: taurine level

Study type: Interventional

Funder types: Other

Identifiers

NCT04193761

HAM00077

Details and patient eligibility

About

Serum taurine level beside (AFP and AFU) are of great value in early diagnosis in HCC Egyptian patients and may have a rule in identifying end-stage liver disease (ESLD) patients candidate for LDLT.

Full description

Taurine has been demonstrated to have a direct and indirect antioxidant effect and to display antineoplastic activity by preventing angiogenesis and enhancing tumor cell apoptosis. Also it was suggested that measurement of serum taurine level in hepatic patients beside fibroscan is of great value in the early diagnosis of any fibrotic and cancerous liver changes.Aim of the work was to correlate serum taurine level with the levels of the specific tumor markers (α- fetoprotein and α-L-fucosidase ) for early diagnosis of different stages of HCC in Egyptian patients.

This observational case-control study was conducted in the Tropical Medicine Department, Ahmed Maher Teaching Hospital. Eighty hepatic patients were assigned to three groups (Chronic hepatitis, Cirrhosis and HCC). Twenty healthy subjects were enrolled as a control group. Serum levels of AFP, AFU, and taurine beside complete biochemical analysis and liver biopsies from all selected patients were done. Patients who accepted to be a candidate for living donor liver transplant (LDLT) were referred to Ain Shams University Specialized Hospital (ASUSH) liver transplant unit.

Enrollment: 100 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Chronic hepatitis
• Cirrhosis
• HCC patients

Exclusion criteria

• Patient refusal
• Bleeding tendency
• Tense ascites
• Inability to obtain a liver biopsy

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 4 patient groups

Control

Active Comparator group

Treatment:

Diagnostic Test: taurine level

Chronic hepatitis

Active Comparator group

Treatment:

Diagnostic Test: taurine level

Cirrhosis

Active Comparator group

Treatment:

Diagnostic Test: taurine level

Hepatocellular carcinoma

Active Comparator group

Treatment:

Diagnostic Test: taurine level